Simulations Plus Releases GastroPlus® X, The Next Generation PBPK/PBBM Modeling and Simulation Software

Redesigned platform offers ease-of-use, enhanced software engineering, and significant productivity gains for users

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, has announced the release of GastroPlus® X.

Branded as GPX™, this new platform represents the next generation of physiologically based pharmacokinetics/ biopharmaceutics (PBPK/PBBM) modeling and simulation software. Utilizing proven top-rated science, advanced models, refined algorithms, and integrated machine learning (ML) technology, GPX offers an entirely updated user experience with an intuitive interface, streamlined workflows, and faster processing.

“GPX is truly a culmination of a long-term collaboration with our partners to understand how we can better support their program needs and enable critical scientific thinking,” said Neil Miller , Vice President of Simulation Sciences at Simulations Plus. “Our development process included significant external user testing, and we sought partners’ feedback throughout the entire development cycle. This resulted in a completely redesigned, intuitive, flexible platform that follows our customers’ research and thought processes instead of requiring them to fit their processes to the software.”

“For more than 25 years, we have remained laser-focused on providing the best science and algorithms on the market. Our commitment to continuous innovation and improvement is why GastroPlus remains the preferred platform for predicting a wide array of applications, including gastrointestinal absorption for oral products, first-in-human outcomes, and food effects,” said John DiBella , President of PBPK Solutions at Simulations Plus. “GPX offers increased functionality that other programs cannot provide, such as true polypharmacy simulations mimicking real-world scenarios. We believe the intuitive design, workflows, and data handling will help us expand our addressable market globally by significantly shortening the learning curves for new users, improving the productivity of experienced modelers, and enhancing critical communication with health authorities. As our clients consider the implications of the FDA’s newly established Quantitative Medicine Center of Excellence, GPX will provide robust support for their regulatory interactions. GPX is truly the most exciting development in PBPK science to launch in many years.”

GPX is designed to be a comprehensive PBPK/PBBM modeling and simulation platform, allowing users to handle everything from early discovery high-throughput PK simulations and drug-drug interactions (DDIs) to population predictions and more all in the same place. Utilization of a single PBPK/PBBM platform, with reusable assets and templates, reduces the time spent on tedious tasks like model setup, importing and exporting data, and reformatting plotted modeling results.

GPX offers flexible deployment options, allowing for both local installation and seamless integration with cloud environments, providing users with the freedom to choose the best setup for their needs.

GPX is available for licensing now. For more information, please contact Renee Bouche at 661-723-7723 or renee.bouche@simulations-plus.com.